New combo therapy aims to stop aggressive bladder cancer from coming back
NCT ID NCT07498907
Summary
This study is testing whether a targeted drug called disitamab vedotin, combined with radiation therapy, works better than standard chemotherapy to prevent cancer from returning after surgery for upper urinary tract cancer. The trial is for patients whose cancer tests positive for a specific marker called HER2 and who cannot receive the usual cisplatin chemotherapy. Researchers will measure how long patients remain cancer-free over three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.